We next compared the expression levels of 4 major activating receptors (NKG2D, NKp30, DNAM-1, and 2B4) and 3 major inhibitory receptors (NKG2A, KIR2DL1, and KIR3DL1) on CD3−CD16brCD56dim cells in newly diagnosed CML patients vs. healthy controls, and in successfully-treated patients who have reached MMR by imatinib, nilotinib, or dasatinib. This evidence concerns the gene KIR2DL1 and chronic myelogenous leukemia, BCR-ABL1 positive.